Abstract. Urinary pyridinoline (pyr) and deoxypyridinoline (dpyr) are new markers for bone resorption, and serum osteocalcin reportedly indicates osteoblastic activity. Recently, a new ultrasound bone densitometer instrument has been developed that measures ultrasonic properties of the os calcis, namely, the speed of sound (SOS), broadband ultrasound attenuation (BUA), and stiffness index. The effects of menopause on biochemical markers and ultrasound densitometry were investigated in 40 healthy females, 36-39 years, with regular menstruation, and in 117 healthy perimenopausal females, 47-57 years, who were divided into a premenopausal group and a postmenopausal group. Significantly elevated values of pyr, dpyr, and serum osteocalcin were found for the postmenopausal group as a whole compared with the premenopausal group. We examined postmenopausal groups 48-57 years of age stratified into 2-year intervals (within 2 years of the menopause, 2-4 years postmenopause and 4-6 years postmenopause). Elevated values of urinary pyr, dpyr, and serum osteocalcin were evident even in the first 2 years postmenopause compared with the premenopausal group, and these higher values were exhibited until 6 years after menopause. We found a significant decrease in SOS, BUA, and stiffness index of the postmenopausal group as a whole, compared with those of the premenopausal group. SOS, BUA, and stiffness index of the group within 2 years of menopause significantly decreased compared with those of the premenopausal group. The Z-scores of the increase in biochemical markers and the decrease in stiffness index in the postmenopausal group were approximately 0.7-1.3 compared with the premenopausal group. The results suggest that these biochemical markers and ultrasound densitometry are potentially sensitive parameters of postmenopausal bone change.
It is generally accepted that estrogen deficiency results in postmenopausal bone loss [1] . Many studies of postmenopausal bone loss have been reported. The concept of the histologic heterogeneity of postmenopausal osteoporosis has been developed based on analysis of iliac crest bone biopsy [2] , whereas histologic data has suggested that increased bone formation is secondarily elevated as a result of the coupling phenomenon induced by a postmenopausal inCorrespondence to: K. Kawana crease in bone resorption [3] . Densitometric data showed that menopause had a greater effect on bone loss than did chronological age [4] , and that the accelerated phase of bone loss occurred early within the first year after menopause and lasted only a few years [5] . Recently, the assay methods for several biochemical markers, specific to bone, and a new ultrasound bone densitometer have been developed. We investigated the effect of menopause on bone metabolism with these recently developed measuring systems.
Biochemical markers have been investigated with regard to the effect of menopause on bone metabolism. These biochemical markers can provide evidence for an overall increase in bone turnover related to bone loss. Hydroxyproline (HPR) has drawn attention as a marker of bone resorption. It is well known that significantly elevated values of urinary HPR/creatinine in postmenopausal subjects was found, compared with premenopausal subjects [4] . However, it has been demonstrated that urinary HPR is metabolized in the liver and is affected by diet [6] .
Pyridinoline (pyr) and deoxypyridinoline (dpyr) are cross-linked intra-and intercollagen molecules. Although pyr and dpyr are distributed to tissues other than bone, the majority of urinary pyr and dpyr are thought to be originally from bone [7] . Subsequent reports have shown that there is a good correlation between the pyr and dpyr concentrations in urine and the bone resorption surface area according to bone biopsies [8] , and that valiaes of urinary pyr and dpyr are elevated in diseases in which bone resorption is accelerated [9] [10] [11] [12] [13] [14] [15] . We previously reported age-related changes of urinary pyr and dpyr in 337 healthy females and revealed that both values in subjects in their 50s were significantly higher than those in their forties [16] . In this study, we focused more precisely on the period of menopause, and investigated peri-and postmenopausal females using urinary pyr and dpyr levels, and compared them with the levels in younger women who were having regular menstrual cycles.
Osteocalcin is a bone-specific protein secreted by osteoblast [17] . Brown et al. [18] demonstrated that serum osteocalcin could serve as an index of bone formation. Serum osteocalcin, measured with radioimmunoassay kits, has been used for investigating the effect of menopause on bone metabolism [19, 20] . In the present study, we investigated the effect of menopause on serum osteocalcin with a newly developed measuring system for human intact osteocalcin based on sandwich enzyme immunoassay (EIA) [21] .
A new ultrasound bone densitometer instrument, the Achilles (Lunar Corporation, Madison, WI), has been developed that is compact and potentially portable, rapid, simple to use, and avoids ionizing radiation. The Achilles measures ultrasonic properties of the os calcis, namely, the speed of The term menopause means that at least 1 year has passed since the last menstruation sound (SOS) and broadband ultrasound attenuation (BUA), and a proprietary factor derived from SOS and BUA, the stiffness index. SOS and BUA measurements seem to reflect not only the density of bone, but SOS also depends on the elasticity, and BUA may relate to bone structure [22, 23] . It was reported that the Achilles measured the ultrasonic properties of the os calcis with good precision and could differentiate between normals and those with osteopenia [24] . Moreover, the mean ultrasound values for each measurement were all significantly smaller for the group of osteoporosis patients than for the group of age-matched controls [25] . In this investigation, we examined the influence of menopause on SOS, BUA, and stiffness index. The aim of this cross-sectional study was to investigate the effect of menopause on the bone metabolism of healthy females, using biochemical markers and ultrasound densitometry of the os calcis.
Materials and Methods

Subjects
The subjects consisted of 157 healthy Japanese females, 36-57 years, who were volunteers and had given their informed consent prior to the study. All were without osteoporosis-associated symptoms (lumbago and/or back pain) and not under medical treatment for conditions known to affect bone metabolism. The subjects were divided into a healthy-30s age group (group PRE1) of 40 subjects with normal menstruation (36-39 years), a premenopausal group (group PRE2) of 62 subjects (47-54 years), and a postmenopausal group of 55 subjects (48-57 years). Premenopausal subjects were divided into two groups: a group of healthy-30s subjects who were having normal and regular menstrual cycles, and a group of premenopausal subjects who were having regular or irregular menstrual cycles and were close to menopause. There was no significant difference in the height, weight, and body mass index among group PREa, group PRE2, and postmenopausal group. In addition, the postmenopausal group was stratified into 2-year intervals: a less than 2-year postmenopausal group (group POST1) of 21 subjects (48-56 years), a 2-4 years postmenopausal group (group POST2) of 17 subjects (50-56 years), and a 4--6 years postmenopausal group (group POST3) of 17 subjects (49-57 years). The term postmenopause was applied to subjects having no menstrual bleeding for at least 1 year since their last menstruation. There was no significant difference in height, weight, and body mass index among group PRE1, group PRE2, group POST1, group POST2, and group POST3. The characteristics of the subject groups are summarized in Table 1 . Fasting urine was collected from the subjects. Also, serum was collected between 9:00 and 11:00 a.m. All samples were stored at -30~ until used.
Measurement of Urinary Pyr and Dpyr
Urinary pyr and dpyr were measured by the method previously described [26] . Briefly, each urine sample (2 ml) was hydrolyzed with an equal volume of concentrated HC1 at ll0~ for 20 hours. The hydrolysate (0.25 ml) was mixed with 15 ml of distilled water and applied to an SP-Sephadex C25 column (0.8 x 1.0 cm). After washing with 20 ml of 0.15 M HCI, pyr and dpyr were eluted with 5 ml of 1.0 M HC1. After evaporation, the residue was dissolved in 200 txl of 1% heptafluorobutyic acid (HFBA) solution. The solutions were stored at -30~ prior to high-performance liquid chromatography (HPLC) analysis. The HPLC system consisted of a Model CCPM pump (TOSOH, TOKYO, Japan), a Model FS-8010 spectrofluorometer (TOSOH), and a Model SC-8010 system controller (TOSOH). A column (8 mm • 10 cm) prepacked with Radial-Pak C18, of 10 ~m particle size, type 8C1810u (Waters Associates, Inc, Milford MA, USA) was used. A mobile phase of acetonitrile/30 mM HFBA (27:73, v/v) was used, with a flow rate of 1.0 ml/minute. The volume of each sample injected was 160 ~zl. The fluorescence at 390 nm was measured on excitation at 297 nm. Before hydrolysis, the urinary creatinine content was determined by the Jaffe method on an aliquot of each urine sample using a Hitachi clinical chemistry automated analyzer (Hitachi, Japan). The values ofpyr and dpyr in the urine samples were expressed per mmol of urinary creatinine.
In this method, the recovery of standards (mean -SD) was 75.4 ---2.3% for pyr, 73.1 -+ 2.9% for dpyr, and the coefficient of variation in the hydrolysate of urine was 4.0% for pyr and 4.2% for dpyr.
Measurement of Serum Osteocalcin
Serum osteocalcin was measured using the sandwich EIA for human intact osteocalcin, as described by Hosoda et al. [21] . As a standard, purified human osteocalcin was prepared at concentrations of 5, 2.5, 1.0, 0.3, 0.1, 0.05, and 0 ng/ml. Two hundred microliters of each of these solutions and 200 Ixl of peroxidase-labeled anti-C7 IgG solution with the anti-N20 IgG-fixed ball were placed in a glass tube. After incubation for 1.5 hours at 37~ each ball was washed three times with saline, then 0.4 ml of tetramethylbenzidine (Dojin Labs., Kumamoto, Japan) and 0.017% hydrogen peroxide were added to the tube, and finally the mixture was incubated at 37~ for 30 minutes. The enzyme-substrate reaction was terminated by adding 1 ml of 1 N H2SO4 and the absorbance was measured at 450 nm. Serum samples were diluted 1:21 and their corresponding human osteocalcin levels were determined by the same immunoassay procedure as that described above.
Using this method, the intra-and interassay coefficients of variation of standards at concentrations of 0.01-1 ng/tube (1-100 ng/ml serum) were 2.4-7.4% and 3.9-7.5%, respectively and those of three serum samples (one normal subject and two uremic patients) were 2.5-5.4% and 4.7-5.7%, respectively.
Measurement of Ultrasound Densitometry
The ultrasonic velocity (SOS in m/s) and the attenuation slope (BUA in dB/MHz) of the os calcis were measured using the Achilles ultrasound bone densitometer (Lunar Corp., Madison, WI). The ultrasound signal was emitted from one transducer and passed through the waterbath in which the heel was placed. The signal was received by the opposing transducer, digitized, and was stored by circuitry in the control box. The PS 11 computer (IBM) then used the obtained data to calculate SOS and BUA. The mathematical index referred to as the stiffness index is also calculated automatically from the combined data from SOS and BUA. This stiffness index is derived by subtracting from the observed SOS the SOS for narrow fat (-1380) and subtracting the lowest BUA (-50) from the observed BUA. This scales the SOS and BUA into biological relevant ranges. The combined BUA and SOS is not equivalent to biochemical stiffness. Belinda et al. found that stiffness index measurements correlated slightly better than BUA or SOS with dual energy X-ray absorptiometry (DXA) bone mineral density (BMD) measurements in spine and femoral neck [24] . In addition, it was reported that the Z-score of osteoporosis patients compared with age-matched controls was higher for stiffness index than for SOS or BUA [25] . These reports showed that stiffness index was a better measure than SOS or BUA alone. The long-term precision errors in vitro were measured on a daily basis over a 6-month period on a polymethylene standard. The short-term precision errors in vivo and in vitro were also measured on 10 occasions over a 2-week period, in five subjects (three young normal subjects and two patients with osteoporosis) and on a polyethylene standard phantom. The long-term precision errors in vitro were 0.3% for SOS and 1.2% for BUA. The short-term precision errors were 0.1% for SOS and 0.9% for BUA, and mean precision errors in vivo were 0.3% for SOS, 1.0% for BUA, and 0.6% for stiffness index [25] .
Statistical Analysis
All values were expressed as mean -+ standard error of the mean (SEM). In expressing the results, decimal places are not used for SOS or BUA as the precision of this measurement does not warrant it; however, decimal places are used for the stiffness index. Differences between the postmenopausal group and group PRE2 in biochemical markers and ultrasound measurements were expressed as a Z-score; the SD from the group PRE2 was used to calculate the Z-score. Probabilities below 5% were considered statistically significant. Comparisons of values of urinary pyr, dpyr, serum osteocalcin, SOS, BUA, and stiffness index among each group were performed using one-way analysis of variance (ANOVA) following the Scheffe F-test method. Comparisons of Z-scores of urinary pyr, dpyr, serum osteocalcin, SOS, BUA, and stiffness were also performed using one-way ANOVA following the Scheffe F-test method. Linear regression analysis was used to determine the degree of correlation between the values of urinary pyr, dpyr, serum osteocalcin, SOS, BUA, and stiffness index. Table 2 shows a comparison of biochemical markers of bone turnover and ultrasound measurements in premenopausal subjects and postmenopausal subjects. The values of urinary pyr, dpyr, serum osteocalcin, SOS, BUA, and stiffness index did not significantly change between the subjects in groups PRE 1 and PRE 2. The values of urinary pyr, dpyr, and serum osteocalcin in the postmenopausal group were significantly higher than those in the subjects in groups PRE 1 and POST2 POST3 PRE 2 . The values of SOS, BUA, and stiffness index in the postmenopausal group were significantly lower than those of the subjects in groups PRE1 and PRE z. The Z-score in the postmenopausal group compared with the PREz group was 0.92 for pyr, 1.24 for dpyr, 1.33 for serum osteocalcin, -0.96 for SOS, -0.74 for BUA, and -1.03 for stiffness index. Table 3 shows a comparison of biochemical markers of bone turnover and ultrasound measurements in the subjects based on the number of years after menopause. The values of urinary pyr and serum osteocalcin in group POST1, POST2, and POST 3 were significantly higher than those in group PRE2. The values of urinary dpyr in group POST1 and POST 2 were significantly higher than in group PRE2, but there was no significant difference between groups PRE z and POST3. The values of SOS and stiffness index in group POST1, POST2, and POST 3 were significantly lower than those in group PRE 2. The values of BUA in group POSTa and POST 3 were significantly lower than those in group PRE z. The values of urinary pyr, dpyr, serum osteocalcin, SOS, and BUA did not significantly change among groups POST1, POST 2, and POST 3. Figure 1 shows the values of biochemical markers of bone turnover in the subjects based on the number of years after menopause. Figure 2 shows the values of ultrasound measurements in the subjects based on the number of years after menopause. As was expected, a significantly higher correlation was observed between urinary pyr and urinary dpyr (r = 0.848, P < 0.001). There were significant but weak correlations between urinary pyr and serum osteocalcin (r = 0.316, P < 0.001) and between urinary dpyr and serum osteocalcin (r = 0.378, P < 0.001) ( Table 4) .
Results
In all subjects, SOS correlated significantly but weakly with urinary pyr, dpyr, and serum osteocalcin (r = 0.25 (P < 0.05), r = 0.29 (P < 0.001), r = 0.39 (P < 0.001), respectively). In all subjects, BUA correlated significantly but weakly with osteocalcin (r = 0.32, P < 0.001), but did not correlate with urinary pyr and dpyr. In all subjects, stiffness index correlated significantly but weakly with urinary pyr, dpyr, and serum osteocalcin (r = 0.22 (P < 0.01), r = 0.26 (P < 0.01), r = 0.44 (P < 0.001), respectively). In groups PREI or PRE2 or a postmenopausal group, each biochemical marker of bone metabolism did not correlate with each ultrasound measurement.
In addition, the postmenopausal group was divided into three groups according to the value of SOS: SOS within the SD of the mean of group PRE1, SOS more than the SD above the mean of group PRE 1, and SOS more than the SD below the mean of group PRE v No significant difference in urinary pyr, dpyr, and serum osteocalcin was seen among these three groups. Using the same stratified analysis with attention to BUA in the postmenopausal group, no significant difference in urinary pyr, dpyr, and serum osteocalcin was seen among the three groups. Using the same stratified analysis with attention to stiffness index in the postmenopausal group, no significant difference in urinary pyr, dpyr, and serum osteocalcin was seen among the three groups. Fig. 1 . The values of biochemical markers of bone turnover in a healthy-30s age group (PRE1), the less than 2-year postmenopausal group (POST1), the 2-4 years postmenopausal group (POST2), and the 4-6 years postmenopausal group (POST3) compared with those of a premenopausal group (PRE2). Data are expressed as mean +-SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Top: urinary pyridinoline (pyr); middle: urinary deoxypyridinoline (dpyr); bottom: serum osteocalcin (OC). 
Discussion
The present investigation represents a cross-sectional study of changes in urinary pyr, dpyr, serum osteocalcin, SOS, BUA, and stiffness index in premenopausal, perimenopausal, and postmenopausal healthy females.
Cross-sectional studies showed that significantly elevated values of pyr and dpyr were found for the postmenopausal group compared with the premenopausal group [27, 28] . Recently, Hassager et al. [29] longitudinally studied the values of pyr and dpyr in 15 healthy women, 45-54 years, and reported that the mean values of pyr and dpyr in postmenopausal subjects were 30-50% higher than those in premenopausal subjects. However, the sample size of the subjects in the longitudinal studies was relatively small.
In a longitudinal study, Nilas and Christiansen [19] reported that in the last premenopausal year, serum osteocalcin increased slightly and then abruptly reached a high level about 1 V2 years after menopause. This high value for serum osteocalcin continued for at least 5 years after menopause. On the other hand, in a cross-sectional study, Pino et al. [20] reported that there was no significant difference between a less than 2-year postmenopausal group and a premenopausal group in the levels of serum osteocalcin and that it was significantly elevated in the 2 years after menopause group, compared with the less than 2-year postmenopausal group.
The results in the present study indicate that the values of urinary pyr, dpyr, and serum osteocalcin were significantly elevated within 2 years after menopause, compared with the premenopausal group. Also, it was revealed that a high turnover condition of bone metabolism continued until 6 years after menopause because the high values of urinary pyr, dpyr, and serum osteocalcin continued up to 6 years after menopause.
The values of SOS, BUA, and stiffness index in the postmenopausal group decreased significantly compared with those of the premenopausal group. Moreover, the values of SOS, BUA, and stiffness index in the less than 2-year postmenopausal group decreased significantly compared with those of the premenopausal group. These results suggest that ultrasonic properties of the os calcis change within 2 years after menopause.
Although the biochemical variation in the biochemical markers makes correlational analysis uncertain, each of the ultrasound parameters in postmenopausal women were not related to biochemical markers in this study. As a static PRE2 POST1POST2POST3 Fig. 2 . The ultrasound measurements of the os calcis in a healthy30s age group (PREx), the less than 2-year postmenopausal group (POST0, the 2-4 years postmenopausal group (POSTz) , and the 4--6 years postmenopausal group (POST3) compared with those of the premenopausal group (PRE2). Data are expressed as mean -+ SEM. *P < 0.05; **P < 0.01; ***P < 0.001. Top: the speed of sound (SOS); middle: the broadband ultrasound attenuation (BUA); bottom: stiffness index. measurement of bone mass may not be representative of the menopausal process at that time, a study of the relationship between the values of biochemical markers and the rate of change in ultrasound values may be needed. Also, ultrasound densitometry in general seems to reflect both bone density and quality but the biochemical markers reflect the rate of remodeling which may be independent of these variables.
In conclusion, urinary pyr, dpyr, and serum osteocalcin show that a high turnover condition of bone metabolism starts within 2 years after menopause. Also, the bone status, represented by ultrasound values, changes within 2 years after menopause. These biochemical markers and ultrasound values of the os calcis appears to hold potential as sensitive parameters of postmenopausal bone change.
